Could Keryx Biopharmaceuticals (KERX) Change Direction After Today’s Huge Increase?

September 17, 2017 - By Linda Rogers

Investors sentiment increased to 1.22 in Q4 2016. Its up 0.15, from 1.07 in 2016Q3. It increased, as 9 investors sold Keryx Biopharmaceuticals shares while 32 reduced holdings. 19 funds opened positions while 31 raised stakes. 65.62 million shares or 1.53% more from 64.63 million shares in 2016Q3 were reported.
10,792 are held by Lpl Fincl Lc. Prudential Finance reported 10,095 shares. Deerfield stated it has 0.31% of its portfolio in Keryx Biopharmaceuticals (NASDAQ:KERX). The Colorado-based Pub Employees Retirement Association Of Colorado has invested 0% in Keryx Biopharmaceuticals (NASDAQ:KERX). Tower Limited Company (Trc) stated it has 5,911 shares or 0% of all its holdings. Northeast Financial Consultants Incorporated invested in 0.12% or 46,100 shares. Rice Hall James Assoc Limited Liability Company has invested 0.38% in Keryx Biopharmaceuticals (NASDAQ:KERX). Northern Tru holds 0% in Keryx Biopharmaceuticals (NASDAQ:KERX) or 957,142 shares. Invesco Ltd invested in 20,545 shares. Pekin Singer Strauss Asset Management Il reported 30,000 shares. Shufro Rose & Limited Liability invested in 72,700 shares or 0.05% of the stock. Blackrock Gru Ltd reported 55,363 shares. The North Carolina-based Bank Of America De has invested 0% in Keryx Biopharmaceuticals (NASDAQ:KERX). Millennium Mngmt Limited Liability has 857,234 shares for 0.01% of their portfolio. Citadel Ltd Liability Company holds 47,309 shares or 0% of its portfolio.

Since April 5, 2017, it had 0 insider buys, and 6 selling transactions for $59,425 activity. Another trade for 642 shares valued at $3,724 was sold by Adams Brian. $5,284 worth of Keryx Biopharmaceuticals (NASDAQ:KERX) was sold by Madison Greg on Wednesday, April 5. $8,603 worth of Keryx Biopharmaceuticals (NASDAQ:KERX) was sold by Holmes Scott A on Monday, May 1. Another trade for 1,441 shares valued at $8,603 was sold by Neylan John F..

The stock of Keryx Biopharmaceuticals (NASDAQ:KERX) is a huge mover today! The stock increased 5.89% or $0.4 on September 15, reaching $7.19. About 3.03M shares traded or 197.06% up from the average. Keryx Biopharmaceuticals (NASDAQ:KERX) has risen 13.56% since September 17, 2016 and is uptrending. It has underperformed by 3.14% the S&P500.
The move comes after 5 months positive chart setup for the $853.81M company. It was reported on Sep, 17 by We have $7.77 PT which if reached, will make NASDAQ:KERX worth $68.30M more.

Wall Street await Keryx Biopharmaceuticals (NASDAQ:KERX) to release earnings on November, 8. Analysts forecast earnings per share of $-0.17, up exactly $0.22 or 56.41 % from 2014’s $-0.39 EPS. After posting $-0.21 EPS for the previous quarter, Keryx Biopharmaceuticals’s analysts now forecast -19.05 % EPS growth.

Keryx Biopharmaceuticals (NASDAQ:KERX) Ratings Coverage

Among 15 analysts covering Keryx Biopharmaceuticals (NASDAQ:KERX), 6 have Buy rating, 2 Sell and 7 Hold. Therefore 40% are positive. Keryx Biopharmaceuticals had 35 analyst reports since July 23, 2015 according to SRatingsIntel. The rating was upgraded by Raymond James on Friday, February 26 to “Outperform”. The stock of Keryx Biopharmaceuticals (NASDAQ:KERX) earned “Sell” rating by Citigroup on Thursday, September 3. The stock has “Buy” rating by Roth Capital on Monday, August 10. JMP Securities maintained Keryx Biopharmaceuticals (NASDAQ:KERX) on Wednesday, March 9 with “Market Outperform” rating. The stock of Keryx Biopharmaceuticals (NASDAQ:KERX) earned “Outperform” rating by Raymond James on Tuesday, August 2. Maxim Group maintained the shares of KERX in report on Friday, July 8 with “Buy” rating. The stock of Keryx Biopharmaceuticals (NASDAQ:KERX) earned “Equal-Weight” rating by Morgan Stanley on Monday, October 5. As per Wednesday, November 9, the company rating was upgraded by Maxim Group. Morgan Stanley initiated Keryx Biopharmaceuticals (NASDAQ:KERX) on Thursday, August 13 with “Underweight” rating. Ladenburg Thalmann maintained Keryx Biopharmaceuticals (NASDAQ:KERX) on Tuesday, August 2 with “Buy” rating.

More notable recent Keryx Biopharmaceuticals (NASDAQ:KERX) news were published by: which released: “Captain Keryx Beams Up Sales” on August 08, 2017, also with their article: “Keryx Biopharmaceuticals Announces Second Quarter 2017 Financial Results and …” published on July 27, 2017, published: “Keryx Biopharmaceuticals: Catalyst In Upcoming FDA Decision” on August 09, 2017. More interesting news about Keryx Biopharmaceuticals (NASDAQ:KERX) were released by: and their article: “Keryx Biopharmaceuticals to Webcast its Presentations at Investor Healthcare …” published on September 05, 2017 as well as‘s news article titled: “Keryx Biopharmaceuticals’ (KERX) CEO Greg Madison on Q1 2017 Results …” with publication date: May 04, 2017.

Keryx Biopharmaceuticals, Inc. is a biopharmaceutical firm focused on the development of medicines for people with renal disease. The company has market cap of $853.81 million. The Firm is engaged in the manufacture, development and commercialization of products for use in treating human diseases. It currently has negative earnings. The Company’s marketed product, Auryxia , which is an orally available, absorbable, iron medicine is approved in the United States for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.